Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO Congress 2019.

2020-04

Lau, David K

Burge, Matthew

Roy, Amitesh

Chau, Ian

Haller, Daniel G

Shapiro, Jeremy D

Peeters, Marc

Pavlakis, Nick

Karapetis, Christos S

Tebbutt, Niall C

Segelov, Eva

Price, Timothy J

BRAF

MSI

RAS

chemotherapy

colorectal

consensus

metastatic

Journal Article

10.1080/14737140.2020.1744439

Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behaviour according to molecular subtype.Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarises expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping.Expert opinion: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. EGFR-targeted antibodies are restricted to patients with extended RAS wild-type profiles, with evidence that they should be further restricted to patients with left-sided tumours. Clinically distinct treatment pathways based on tumour RAS, BRAF, HER2 and MMR status, are now clinically applicable. Evidence suggests therapy for additional subgroups will soon be defined; the most advanced being for patients with KRAS G12C mutation and gene TRK fusion defects.

link

Expert Review of Anticancer Therapy 2020; 20(4): 251-270

Expert Review of Anticancer Therapy